Database

Startups

Main Industry
Health Care
Main Product/Service
Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre
Founded Year
2014
Unified Business No.
24571303
Status
Active
Number of Employees
0
Total Paid-in Capital
846,050,000 (NT$)
Location of Company
Taiwan , Hsinchu County
Exit Status
Emerging Stock Exchange(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
Taiwan Bio is dedicated to driving innovation and expanding access to cell therapies. Through our FAST CGT platform, we reduce costs, enhance efficacy, accelerate development, and streamline production, setting new milestones in the treatment of chronic a



More ↓

Similar Companies

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

GenomeFrontier Therapeutics TW Co., Ltd.

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

Ochre Bio Taiwan Ltd

Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl